UK GLP-1 prescribing tracker

Methodology

• · Source: NHSBSA English Prescribing Dataset (EPD) with SNOMED Code, published monthly by the NHS Business Services Authority under the Open Government Licence v3.0. This is the same open feed that OpenPrescribing.net builds on.
• · What we count: the monthly SUM of prescription items, total quantity, and NHS actual cost across the six GLP-1 receptor agonist chemical substances in English primary-care prescribing (semaglutide, tirzepatide, dulaglutide, liraglutide, exenatide, lixisenatide), grouped by BNF chemical substance.
• · Scope: England primary care only (GP and community prescribing). The dataset excludes hospital prescribing and the entire private clinic and online pharmacy market, so true UK GLP-1 use is higher than these figures.
• · Indication caveat: the same chemical substances are licensed for type 2 diabetes and for weight management. Prescription data cannot be split by indication, so these counts cover both.
• · Cost caveat: NHS actual cost is what the NHS pays after discounts and adjustments. It is not a consumer price and says nothing about private-market pricing.
• · Cadence: NHSBSA publishes each month with a lag of several weeks. This page refreshes when we re-run the fetch against the portal; latest published month shown: August 2026. Page data last fetched 2026-10-28.

### Monthly GLP-1 prescription items and NHS actual cost, England primary care, latest 12 published months (to August 2026)

| Month | Prescription items | NHS actual cost |
| --- | --- | --- |
| Sept 2025 | 466,429 | £80.4m |
| Oct 2025 | 462,548 | £79.0m |
| Nov 2025 | 432,095 | £74.6m |
| Dec 2025 | 479,088 | £83.4m |
| Jan 2026 | 470,397 | £82.4m |
| Feb 2026 | 434,333 | £76.6m |
| Mar 2026 | 488,850 | £86.5m |
| Apr 2026 | 490,110 | £86.8m |
| May 2026 | 491,675 | £87.7m |
| Jun 2026 | 528,608 | £94.8m |
| Jul 2026 | 565,747 | £102.2m |
| Aug 2026 | 525,609 | £98.0m |

Source: NHSBSA English Prescribing Dataset (Open Government Licence v3.0), GLP-1 receptor agonist chemical substances, summed by month

Items are dispensed prescription items, not a patient headcount, and cover all licensed uses (indication cannot be split). England primary care only; hospital and private prescribing excluded. Data last fetched 2026-10-28. Information only, not medical advice.

Related: UK peptide and weight-loss medication statistics · GLP-1 cost and supply in the UK · NHS access routes